nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Dimetacrine—ACHE—prostate cancer	0.00232	0.0805	CrCbGaD
Doxylamine—Tamoxifen—SULT1A1—prostate cancer	0.00219	0.0759	CrCbGaD
Doxylamine—Disopyramide—SLC22A1—prostate cancer	0.00115	0.0399	CrCbGaD
Doxylamine—Toremifene—ESR1—prostate cancer	0.000951	0.0329	CrCbGaD
Doxylamine—Chlorphenamine—SLC22A1—prostate cancer	0.00084	0.0291	CrCbGaD
Doxylamine—Toremifene—CYP1A1—prostate cancer	0.00076	0.0263	CrCbGaD
Doxylamine—Levomethadyl Acetate—CYP3A5—prostate cancer	0.000757	0.0262	CrCbGaD
Doxylamine—Diphenhydramine—CYP2C18—prostate cancer	0.000698	0.0242	CrCbGaD
Doxylamine—Levomethadyl Acetate—CYP19A1—prostate cancer	0.000698	0.0242	CrCbGaD
Doxylamine—Chlorphenamine—CYP3A5—prostate cancer	0.000677	0.0235	CrCbGaD
Doxylamine—Methadone—CYP2C18—prostate cancer	0.000674	0.0233	CrCbGaD
Doxylamine—Tamoxifen—ESR2—prostate cancer	0.000616	0.0213	CrCbGaD
Doxylamine—Clemastine—CYP3A4—prostate cancer	0.000612	0.0212	CrCbGaD
Doxylamine—Erythema—Capecitabine—prostate cancer	0.000601	0.000622	CcSEcCtD
Doxylamine—Imipramine—SLC22A3—prostate cancer	0.0006	0.0208	CrCbGaD
Doxylamine—Dehydration—Doxorubicin—prostate cancer	0.000598	0.000619	CcSEcCtD
Doxylamine—Thrombocytopenia—Etoposide—prostate cancer	0.000597	0.000618	CcSEcCtD
Doxylamine—Muscle spasms—Docetaxel—prostate cancer	0.000597	0.000618	CcSEcCtD
Doxylamine—Tachycardia—Etoposide—prostate cancer	0.000595	0.000616	CcSEcCtD
Doxylamine—Nausea—Goserelin—prostate cancer	0.000589	0.00061	CcSEcCtD
Doxylamine—Hyperhidrosis—Etoposide—prostate cancer	0.000589	0.00061	CcSEcCtD
Doxylamine—Pancreatitis—Epirubicin—prostate cancer	0.000589	0.00061	CcSEcCtD
Doxylamine—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000588	0.000608	CcSEcCtD
Doxylamine—Nausea—Conjugated Estrogens—prostate cancer	0.000584	0.000604	CcSEcCtD
Doxylamine—Urticaria—Mitoxantrone—prostate cancer	0.000582	0.000603	CcSEcCtD
Doxylamine—Breast disorder—Doxorubicin—prostate cancer	0.000581	0.000602	CcSEcCtD
Doxylamine—Anorexia—Etoposide—prostate cancer	0.000581	0.000601	CcSEcCtD
Doxylamine—Hypersensitivity—Estradiol—prostate cancer	0.00058	0.0006	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	0.000579	0.000599	CcSEcCtD
Doxylamine—Muscle spasms—Capecitabine—prostate cancer	0.000578	0.000598	CcSEcCtD
Doxylamine—Nasopharyngitis—Doxorubicin—prostate cancer	0.000575	0.000595	CcSEcCtD
Doxylamine—Eye disorder—Prednisone—prostate cancer	0.000575	0.000595	CcSEcCtD
Doxylamine—Flushing—Prednisone—prostate cancer	0.000571	0.000591	CcSEcCtD
Doxylamine—Pancytopenia—Epirubicin—prostate cancer	0.000571	0.000591	CcSEcCtD
Doxylamine—Hypotension—Etoposide—prostate cancer	0.00057	0.00059	CcSEcCtD
Doxylamine—Diphenhydramine—SLC22A1—prostate cancer	0.00057	0.0197	CrCbGaD
Doxylamine—Asthenia—Estradiol—prostate cancer	0.000564	0.000584	CcSEcCtD
Doxylamine—Tremor—Capecitabine—prostate cancer	0.000563	0.000583	CcSEcCtD
Doxylamine—Tamoxifen—CYP1B1—prostate cancer	0.000562	0.0195	CrCbGaD
Doxylamine—Ill-defined disorder—Capecitabine—prostate cancer	0.000558	0.000577	CcSEcCtD
Doxylamine—Pruritus—Estradiol—prostate cancer	0.000557	0.000576	CcSEcCtD
Doxylamine—Leukopenia—Docetaxel—prostate cancer	0.000556	0.000575	CcSEcCtD
Doxylamine—Immune system disorder—Prednisone—prostate cancer	0.000556	0.000575	CcSEcCtD
Doxylamine—Palpitations—Docetaxel—prostate cancer	0.000549	0.000568	CcSEcCtD
Doxylamine—Carbinoxamine—CYP2E1—prostate cancer	0.000548	0.019	CrCbGaD
Doxylamine—Pancreatitis—Doxorubicin—prostate cancer	0.000545	0.000564	CcSEcCtD
Doxylamine—Dyspnoea—Etoposide—prostate cancer	0.000544	0.000562	CcSEcCtD
Doxylamine—Carbinoxamine—CYP2C19—prostate cancer	0.000542	0.0188	CrCbGaD
Doxylamine—Malaise—Capecitabine—prostate cancer	0.000542	0.000561	CcSEcCtD
Doxylamine—Somnolence—Etoposide—prostate cancer	0.000542	0.000561	CcSEcCtD
Doxylamine—Vertigo—Capecitabine—prostate cancer	0.00054	0.000559	CcSEcCtD
Doxylamine—Hypersensitivity—Mitoxantrone—prostate cancer	0.00054	0.000559	CcSEcCtD
Doxylamine—Diarrhoea—Estradiol—prostate cancer	0.000538	0.000557	CcSEcCtD
Doxylamine—Leukopenia—Capecitabine—prostate cancer	0.000538	0.000557	CcSEcCtD
Doxylamine—Convulsion—Docetaxel—prostate cancer	0.000538	0.000557	CcSEcCtD
Doxylamine—Drowsiness—Epirubicin—prostate cancer	0.000536	0.000554	CcSEcCtD
Doxylamine—Erythema—Prednisone—prostate cancer	0.000535	0.000554	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000531	0.00055	CcSEcCtD
Doxylamine—Palpitations—Capecitabine—prostate cancer	0.000531	0.00055	CcSEcCtD
Doxylamine—Decreased appetite—Etoposide—prostate cancer	0.00053	0.000548	CcSEcCtD
Doxylamine—Pancytopenia—Doxorubicin—prostate cancer	0.000528	0.000546	CcSEcCtD
Doxylamine—Imipramine—CYP2C18—prostate cancer	0.000527	0.0183	CrCbGaD
Doxylamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000526	0.000545	CcSEcCtD
Doxylamine—Asthenia—Mitoxantrone—prostate cancer	0.000526	0.000544	CcSEcCtD
Doxylamine—Fatigue—Etoposide—prostate cancer	0.000526	0.000544	CcSEcCtD
Doxylamine—Constipation—Etoposide—prostate cancer	0.000521	0.000539	CcSEcCtD
Doxylamine—Dizziness—Estradiol—prostate cancer	0.00052	0.000538	CcSEcCtD
Doxylamine—Dry mouth—Docetaxel—prostate cancer	0.000517	0.000535	CcSEcCtD
Doxylamine—Sweating—Epirubicin—prostate cancer	0.000514	0.000532	CcSEcCtD
Doxylamine—Confusional state—Docetaxel—prostate cancer	0.000511	0.000529	CcSEcCtD
Doxylamine—Anxiety—Capecitabine—prostate cancer	0.00051	0.000528	CcSEcCtD
Doxylamine—Anaphylactic shock—Docetaxel—prostate cancer	0.000507	0.000524	CcSEcCtD
Doxylamine—Discomfort—Capecitabine—prostate cancer	0.000506	0.000523	CcSEcCtD
Doxylamine—Feeling abnormal—Etoposide—prostate cancer	0.000502	0.00052	CcSEcCtD
Doxylamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000502	0.000519	CcSEcCtD
Doxylamine—Dry mouth—Capecitabine—prostate cancer	0.000501	0.000518	CcSEcCtD
Doxylamine—Vomiting—Estradiol—prostate cancer	0.0005	0.000518	CcSEcCtD
Doxylamine—Agranulocytosis—Epirubicin—prostate cancer	0.0005	0.000517	CcSEcCtD
Doxylamine—Nervous system disorder—Docetaxel—prostate cancer	0.000497	0.000514	CcSEcCtD
Doxylamine—Ill-defined disorder—Prednisone—prostate cancer	0.000497	0.000514	CcSEcCtD
Doxylamine—Thrombocytopenia—Docetaxel—prostate cancer	0.000496	0.000513	CcSEcCtD
Doxylamine—Rash—Estradiol—prostate cancer	0.000496	0.000513	CcSEcCtD
Doxylamine—Drowsiness—Doxorubicin—prostate cancer	0.000496	0.000513	CcSEcCtD
Doxylamine—Dermatitis—Estradiol—prostate cancer	0.000496	0.000513	CcSEcCtD
Doxylamine—Confusional state—Capecitabine—prostate cancer	0.000495	0.000512	CcSEcCtD
Doxylamine—Tachycardia—Docetaxel—prostate cancer	0.000495	0.000512	CcSEcCtD
Doxylamine—Agitation—Prednisone—prostate cancer	0.000492	0.000509	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000492	0.000509	CcSEcCtD
Doxylamine—Bradycardia—Epirubicin—prostate cancer	0.00049	0.000507	CcSEcCtD
Doxylamine—Angioedema—Prednisone—prostate cancer	0.000489	0.000506	CcSEcCtD
Doxylamine—Toremifene—CYP3A4—prostate cancer	0.000485	0.0168	CrCbGaD
Doxylamine—Urticaria—Etoposide—prostate cancer	0.000484	0.000501	CcSEcCtD
Doxylamine—Anorexia—Docetaxel—prostate cancer	0.000483	0.0005	CcSEcCtD
Doxylamine—Malaise—Prednisone—prostate cancer	0.000483	0.0005	CcSEcCtD
Doxylamine—Nervous system disorder—Capecitabine—prostate cancer	0.000481	0.000498	CcSEcCtD
Doxylamine—Vertigo—Prednisone—prostate cancer	0.000481	0.000498	CcSEcCtD
Doxylamine—Hepatitis—Epirubicin—prostate cancer	0.000481	0.000498	CcSEcCtD
Doxylamine—Thrombocytopenia—Capecitabine—prostate cancer	0.00048	0.000497	CcSEcCtD
Doxylamine—Tachycardia—Capecitabine—prostate cancer	0.000479	0.000495	CcSEcCtD
Doxylamine—Sweating—Doxorubicin—prostate cancer	0.000475	0.000492	CcSEcCtD
Doxylamine—Urinary tract disorder—Epirubicin—prostate cancer	0.000475	0.000492	CcSEcCtD
Doxylamine—Brompheniramine—CYP2E1—prostate cancer	0.000474	0.0164	CrCbGaD
Doxylamine—Hyperhidrosis—Capecitabine—prostate cancer	0.000474	0.000491	CcSEcCtD
Doxylamine—Hypotension—Docetaxel—prostate cancer	0.000474	0.00049	CcSEcCtD
Doxylamine—Urethral disorder—Epirubicin—prostate cancer	0.000472	0.000488	CcSEcCtD
Doxylamine—Brompheniramine—CYP2C19—prostate cancer	0.00047	0.0163	CrCbGaD
Doxylamine—Anorexia—Capecitabine—prostate cancer	0.000468	0.000484	CcSEcCtD
Doxylamine—Nausea—Estradiol—prostate cancer	0.000467	0.000483	CcSEcCtD
Doxylamine—Vomiting—Mitoxantrone—prostate cancer	0.000466	0.000482	CcSEcCtD
Doxylamine—Convulsion—Prednisone—prostate cancer	0.000464	0.00048	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—prostate cancer	0.000463	0.000479	CcSEcCtD
Doxylamine—Rash—Mitoxantrone—prostate cancer	0.000462	0.000478	CcSEcCtD
Doxylamine—Dermatitis—Mitoxantrone—prostate cancer	0.000462	0.000478	CcSEcCtD
Doxylamine—Hypotension—Capecitabine—prostate cancer	0.000458	0.000474	CcSEcCtD
Doxylamine—Insomnia—Docetaxel—prostate cancer	0.000458	0.000474	CcSEcCtD
Doxylamine—Erythema multiforme—Epirubicin—prostate cancer	0.000455	0.000471	CcSEcCtD
Doxylamine—Anxiety—Prednisone—prostate cancer	0.000454	0.00047	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—prostate cancer	0.000453	0.000469	CcSEcCtD
Doxylamine—Dyspnoea—Docetaxel—prostate cancer	0.000452	0.000467	CcSEcCtD
Doxylamine—Somnolence—Docetaxel—prostate cancer	0.00045	0.000466	CcSEcCtD
Doxylamine—Discomfort—Prednisone—prostate cancer	0.00045	0.000466	CcSEcCtD
Doxylamine—Eye disorder—Epirubicin—prostate cancer	0.00045	0.000465	CcSEcCtD
Doxylamine—Hypersensitivity—Etoposide—prostate cancer	0.000449	0.000465	CcSEcCtD
Doxylamine—Tamoxifen—CYP3A5—prostate cancer	0.000448	0.0155	CrCbGaD
Doxylamine—Flushing—Epirubicin—prostate cancer	0.000446	0.000462	CcSEcCtD
Doxylamine—Cardiac disorder—Epirubicin—prostate cancer	0.000446	0.000462	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—prostate cancer	0.000445	0.000461	CcSEcCtD
Doxylamine—Methadone—CYP3A5—prostate cancer	0.000444	0.0154	CrCbGaD
Doxylamine—Insomnia—Capecitabine—prostate cancer	0.000444	0.000459	CcSEcCtD
Doxylamine—Decreased appetite—Docetaxel—prostate cancer	0.00044	0.000456	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—prostate cancer	0.00044	0.000455	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000437	0.000453	CcSEcCtD
Doxylamine—Asthenia—Etoposide—prostate cancer	0.000437	0.000453	CcSEcCtD
Doxylamine—Dyspnoea—Capecitabine—prostate cancer	0.000437	0.000453	CcSEcCtD
Doxylamine—Anaphylactic shock—Prednisone—prostate cancer	0.000437	0.000452	CcSEcCtD
Doxylamine—Fatigue—Docetaxel—prostate cancer	0.000437	0.000452	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—prostate cancer	0.000436	0.000451	CcSEcCtD
Doxylamine—Nausea—Mitoxantrone—prostate cancer	0.000435	0.000451	CcSEcCtD
Doxylamine—Immune system disorder—Epirubicin—prostate cancer	0.000435	0.00045	CcSEcCtD
Doxylamine—Mediastinal disorder—Epirubicin—prostate cancer	0.000434	0.000449	CcSEcCtD
Doxylamine—Constipation—Docetaxel—prostate cancer	0.000433	0.000448	CcSEcCtD
Doxylamine—Tamoxifen—CYP2A6—prostate cancer	0.000433	0.015	CrCbGaD
Doxylamine—Pruritus—Etoposide—prostate cancer	0.000431	0.000446	CcSEcCtD
Doxylamine—Imipramine—SLC22A1—prostate cancer	0.00043	0.0149	CrCbGaD
Doxylamine—Nervous system disorder—Prednisone—prostate cancer	0.000429	0.000443	CcSEcCtD
Doxylamine—Tachycardia—Prednisone—prostate cancer	0.000427	0.000441	CcSEcCtD
Doxylamine—Decreased appetite—Capecitabine—prostate cancer	0.000426	0.000441	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000424	0.000438	CcSEcCtD
Doxylamine—Fatigue—Capecitabine—prostate cancer	0.000423	0.000438	CcSEcCtD
Doxylamine—Hyperhidrosis—Prednisone—prostate cancer	0.000422	0.000437	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—prostate cancer	0.000421	0.000435	CcSEcCtD
Doxylamine—Constipation—Capecitabine—prostate cancer	0.00042	0.000434	CcSEcCtD
Doxylamine—Cyclobenzaprine—CYP3A4—prostate cancer	0.000419	0.0145	CrCbGaD
Doxylamine—Erythema—Epirubicin—prostate cancer	0.000419	0.000433	CcSEcCtD
Doxylamine—Feeling abnormal—Docetaxel—prostate cancer	0.000418	0.000432	CcSEcCtD
Doxylamine—Diarrhoea—Etoposide—prostate cancer	0.000417	0.000432	CcSEcCtD
Doxylamine—Anorexia—Prednisone—prostate cancer	0.000417	0.000431	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—prostate cancer	0.000416	0.00043	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—prostate cancer	0.000413	0.000427	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—prostate cancer	0.000413	0.000427	CcSEcCtD
Doxylamine—Tamoxifen—CYP19A1—prostate cancer	0.000413	0.0143	CrCbGaD
Doxylamine—Methadone—CYP19A1—prostate cancer	0.000409	0.0142	CrCbGaD
Doxylamine—Feeling abnormal—Capecitabine—prostate cancer	0.000404	0.000418	CcSEcCtD
Doxylamine—Dizziness—Etoposide—prostate cancer	0.000403	0.000417	CcSEcCtD
Doxylamine—Muscle spasms—Epirubicin—prostate cancer	0.000403	0.000417	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—prostate cancer	0.000402	0.000416	CcSEcCtD
Doxylamine—Disopyramide—CYP3A4—prostate cancer	0.000402	0.0139	CrCbGaD
Doxylamine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000401	0.000415	CcSEcCtD
Doxylamine—Insomnia—Prednisone—prostate cancer	0.000395	0.000409	CcSEcCtD
Doxylamine—Urticaria—Capecitabine—prostate cancer	0.00039	0.000403	CcSEcCtD
Doxylamine—Ill-defined disorder—Epirubicin—prostate cancer	0.000389	0.000402	CcSEcCtD
Doxylamine—Vomiting—Etoposide—prostate cancer	0.000388	0.000401	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—prostate cancer	0.000387	0.000401	CcSEcCtD
Doxylamine—Atomoxetine—CYP2C19—prostate cancer	0.000387	0.0134	CrCbGaD
Doxylamine—Agitation—Epirubicin—prostate cancer	0.000385	0.000398	CcSEcCtD
Doxylamine—Rash—Etoposide—prostate cancer	0.000384	0.000398	CcSEcCtD
Doxylamine—Dermatitis—Etoposide—prostate cancer	0.000384	0.000397	CcSEcCtD
Doxylamine—Decreased appetite—Prednisone—prostate cancer	0.00038	0.000393	CcSEcCtD
Doxylamine—Tamoxifen—ESR1—prostate cancer	0.00038	0.0132	CrCbGaD
Doxylamine—Malaise—Epirubicin—prostate cancer	0.000378	0.000391	CcSEcCtD
Doxylamine—Fatigue—Prednisone—prostate cancer	0.000377	0.00039	CcSEcCtD
Doxylamine—Vertigo—Epirubicin—prostate cancer	0.000376	0.000389	CcSEcCtD
Doxylamine—Leukopenia—Epirubicin—prostate cancer	0.000375	0.000388	CcSEcCtD
Doxylamine—Constipation—Prednisone—prostate cancer	0.000374	0.000387	CcSEcCtD
Doxylamine—Hypersensitivity—Docetaxel—prostate cancer	0.000373	0.000386	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—prostate cancer	0.000373	0.000385	CcSEcCtD
Doxylamine—Palpitations—Epirubicin—prostate cancer	0.00037	0.000383	CcSEcCtD
Doxylamine—Asthenia—Docetaxel—prostate cancer	0.000364	0.000376	CcSEcCtD
Doxylamine—Convulsion—Epirubicin—prostate cancer	0.000363	0.000375	CcSEcCtD
Doxylamine—Nausea—Etoposide—prostate cancer	0.000362	0.000375	CcSEcCtD
Doxylamine—Hypersensitivity—Capecitabine—prostate cancer	0.000361	0.000374	CcSEcCtD
Doxylamine—Feeling abnormal—Prednisone—prostate cancer	0.00036	0.000373	CcSEcCtD
Doxylamine—Ill-defined disorder—Doxorubicin—prostate cancer	0.00036	0.000372	CcSEcCtD
Doxylamine—Pruritus—Docetaxel—prostate cancer	0.000359	0.000371	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—prostate cancer	0.000356	0.000368	CcSEcCtD
Doxylamine—Anxiety—Epirubicin—prostate cancer	0.000355	0.000368	CcSEcCtD
Doxylamine—Discomfort—Epirubicin—prostate cancer	0.000352	0.000364	CcSEcCtD
Doxylamine—Asthenia—Capecitabine—prostate cancer	0.000352	0.000364	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—prostate cancer	0.000349	0.000362	CcSEcCtD
Doxylamine—Dry mouth—Epirubicin—prostate cancer	0.000349	0.000361	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—prostate cancer	0.000348	0.00036	CcSEcCtD
Doxylamine—Urticaria—Prednisone—prostate cancer	0.000347	0.000359	CcSEcCtD
Doxylamine—Pruritus—Capecitabine—prostate cancer	0.000347	0.000359	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—prostate cancer	0.000347	0.000359	CcSEcCtD
Doxylamine—Diarrhoea—Docetaxel—prostate cancer	0.000347	0.000359	CcSEcCtD
Doxylamine—Amitriptyline—CYP3A5—prostate cancer	0.000345	0.012	CrCbGaD
Doxylamine—Carbinoxamine—CYP3A4—prostate cancer	0.000345	0.0119	CrCbGaD
Doxylamine—Confusional state—Epirubicin—prostate cancer	0.000345	0.000357	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—prostate cancer	0.000342	0.000354	CcSEcCtD
Doxylamine—Anaphylactic shock—Epirubicin—prostate cancer	0.000342	0.000354	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—prostate cancer	0.000336	0.000347	CcSEcCtD
Doxylamine—Diarrhoea—Capecitabine—prostate cancer	0.000336	0.000347	CcSEcCtD
Doxylamine—Nervous system disorder—Epirubicin—prostate cancer	0.000335	0.000347	CcSEcCtD
Doxylamine—Dizziness—Docetaxel—prostate cancer	0.000335	0.000347	CcSEcCtD
Doxylamine—Thrombocytopenia—Epirubicin—prostate cancer	0.000335	0.000346	CcSEcCtD
Doxylamine—Tachycardia—Epirubicin—prostate cancer	0.000334	0.000345	CcSEcCtD
Doxylamine—Hyperhidrosis—Epirubicin—prostate cancer	0.00033	0.000342	CcSEcCtD
Doxylamine—Anxiety—Doxorubicin—prostate cancer	0.000329	0.00034	CcSEcCtD
Doxylamine—Levomethadyl Acetate—CYP3A4—prostate cancer	0.000328	0.0114	CrCbGaD
Doxylamine—Discomfort—Doxorubicin—prostate cancer	0.000326	0.000337	CcSEcCtD
Doxylamine—Anorexia—Epirubicin—prostate cancer	0.000326	0.000337	CcSEcCtD
Doxylamine—Dizziness—Capecitabine—prostate cancer	0.000324	0.000336	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—prostate cancer	0.000323	0.000334	CcSEcCtD
Doxylamine—Vomiting—Docetaxel—prostate cancer	0.000322	0.000333	CcSEcCtD
Doxylamine—Hypersensitivity—Prednisone—prostate cancer	0.000322	0.000333	CcSEcCtD
Doxylamine—Rash—Docetaxel—prostate cancer	0.00032	0.000331	CcSEcCtD
Doxylamine—Hypotension—Epirubicin—prostate cancer	0.000319	0.00033	CcSEcCtD
Doxylamine—Dermatitis—Docetaxel—prostate cancer	0.000319	0.00033	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—prostate cancer	0.000319	0.00033	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—prostate cancer	0.000316	0.000327	CcSEcCtD
Doxylamine—Asthenia—Prednisone—prostate cancer	0.000314	0.000324	CcSEcCtD
Doxylamine—Diphenhydramine—CYP2C19—prostate cancer	0.000313	0.0108	CrCbGaD
Doxylamine—Vomiting—Capecitabine—prostate cancer	0.000312	0.000323	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—prostate cancer	0.00031	0.000321	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—prostate cancer	0.00031	0.00032	CcSEcCtD
Doxylamine—Rash—Capecitabine—prostate cancer	0.000309	0.00032	CcSEcCtD
Doxylamine—Pruritus—Prednisone—prostate cancer	0.000309	0.00032	CcSEcCtD
Doxylamine—Insomnia—Epirubicin—prostate cancer	0.000309	0.00032	CcSEcCtD
Doxylamine—Dermatitis—Capecitabine—prostate cancer	0.000309	0.00032	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—prostate cancer	0.000309	0.000319	CcSEcCtD
Doxylamine—Tamoxifen—CYP2E1—prostate cancer	0.000308	0.0107	CrCbGaD
Doxylamine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000306	0.000316	CcSEcCtD
Doxylamine—Dyspnoea—Epirubicin—prostate cancer	0.000305	0.000315	CcSEcCtD
Doxylamine—Tamoxifen—CYP2C19—prostate cancer	0.000305	0.0106	CrCbGaD
Doxylamine—Somnolence—Epirubicin—prostate cancer	0.000304	0.000314	CcSEcCtD
Doxylamine—Doxepin—CYP2C19—prostate cancer	0.000304	0.0105	CrCbGaD
Doxylamine—Tamoxifen—CYP1A1—prostate cancer	0.000303	0.0105	CrCbGaD
Doxylamine—Methadone—CYP2C19—prostate cancer	0.000302	0.0105	CrCbGaD
Doxylamine—Anorexia—Doxorubicin—prostate cancer	0.000301	0.000312	CcSEcCtD
Doxylamine—Nausea—Docetaxel—prostate cancer	0.000301	0.000311	CcSEcCtD
Doxylamine—Diarrhoea—Prednisone—prostate cancer	0.000299	0.000309	CcSEcCtD
Doxylamine—Orphenadrine—CYP2E1—prostate cancer	0.000299	0.0104	CrCbGaD
Doxylamine—Brompheniramine—CYP3A4—prostate cancer	0.000299	0.0103	CrCbGaD
Doxylamine—Decreased appetite—Epirubicin—prostate cancer	0.000297	0.000307	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—prostate cancer	0.000296	0.000306	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000295	0.000305	CcSEcCtD
Doxylamine—Fatigue—Epirubicin—prostate cancer	0.000295	0.000305	CcSEcCtD
Doxylamine—Chlorphenamine—CYP3A4—prostate cancer	0.000293	0.0102	CrCbGaD
Doxylamine—Constipation—Epirubicin—prostate cancer	0.000292	0.000302	CcSEcCtD
Doxylamine—Nausea—Capecitabine—prostate cancer	0.000291	0.000302	CcSEcCtD
Doxylamine—Dizziness—Prednisone—prostate cancer	0.000289	0.000299	CcSEcCtD
Doxylamine—Insomnia—Doxorubicin—prostate cancer	0.000286	0.000296	CcSEcCtD
Doxylamine—Dextropropoxyphene—CYP3A4—prostate cancer	0.000283	0.00981	CrCbGaD
Doxylamine—Dyspnoea—Doxorubicin—prostate cancer	0.000282	0.000292	CcSEcCtD
Doxylamine—Feeling abnormal—Epirubicin—prostate cancer	0.000282	0.000291	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—prostate cancer	0.000281	0.000291	CcSEcCtD
Doxylamine—Vomiting—Prednisone—prostate cancer	0.000278	0.000287	CcSEcCtD
Doxylamine—Rash—Prednisone—prostate cancer	0.000276	0.000285	CcSEcCtD
Doxylamine—Dermatitis—Prednisone—prostate cancer	0.000275	0.000285	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—prostate cancer	0.000275	0.000284	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000273	0.000282	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—prostate cancer	0.000273	0.000282	CcSEcCtD
Doxylamine—Urticaria—Epirubicin—prostate cancer	0.000272	0.000281	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—prostate cancer	0.00027	0.00028	CcSEcCtD
Doxylamine—Promazine—CYP2C19—prostate cancer	0.00027	0.00935	CrCbGaD
Doxylamine—Feeling abnormal—Doxorubicin—prostate cancer	0.000261	0.00027	CcSEcCtD
Doxylamine—Nausea—Prednisone—prostate cancer	0.00026	0.000269	CcSEcCtD
Doxylamine—Hypersensitivity—Epirubicin—prostate cancer	0.000252	0.000261	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—prostate cancer	0.000251	0.00026	CcSEcCtD
Doxylamine—Benzphetamine—CYP3A4—prostate cancer	0.000248	0.0086	CrCbGaD
Doxylamine—Atomoxetine—CYP3A4—prostate cancer	0.000246	0.00853	CrCbGaD
Doxylamine—Asthenia—Epirubicin—prostate cancer	0.000245	0.000254	CcSEcCtD
Doxylamine—Pruritus—Epirubicin—prostate cancer	0.000242	0.00025	CcSEcCtD
Doxylamine—Imipramine—CYP2E1—prostate cancer	0.000239	0.00827	CrCbGaD
Doxylamine—Amitriptyline—CYP2E1—prostate cancer	0.000237	0.00822	CrCbGaD
Doxylamine—Imipramine—CYP2C19—prostate cancer	0.000236	0.00819	CrCbGaD
Doxylamine—Amitriptyline—CYP2C19—prostate cancer	0.000235	0.00814	CrCbGaD
Doxylamine—Diarrhoea—Epirubicin—prostate cancer	0.000234	0.000242	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—prostate cancer	0.000233	0.000241	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—prostate cancer	0.000227	0.000235	CcSEcCtD
Doxylamine—Dizziness—Epirubicin—prostate cancer	0.000226	0.000234	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—prostate cancer	0.000224	0.000231	CcSEcCtD
Doxylamine—Vomiting—Epirubicin—prostate cancer	0.000217	0.000225	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—prostate cancer	0.000216	0.000224	CcSEcCtD
Doxylamine—Rash—Epirubicin—prostate cancer	0.000216	0.000223	CcSEcCtD
Doxylamine—Dermatitis—Epirubicin—prostate cancer	0.000215	0.000223	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—prostate cancer	0.000209	0.000216	CcSEcCtD
Doxylamine—Nausea—Epirubicin—prostate cancer	0.000203	0.00021	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—prostate cancer	0.000201	0.000208	CcSEcCtD
Doxylamine—Rash—Doxorubicin—prostate cancer	0.000199	0.000206	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—prostate cancer	0.000199	0.000206	CcSEcCtD
Doxylamine—Tamoxifen—CYP3A4—prostate cancer	0.000194	0.00671	CrCbGaD
Doxylamine—Doxepin—CYP3A4—prostate cancer	0.000193	0.00669	CrCbGaD
Doxylamine—Methadone—CYP3A4—prostate cancer	0.000192	0.00665	CrCbGaD
Doxylamine—Orphenadrine—CYP3A4—prostate cancer	0.000188	0.00652	CrCbGaD
Doxylamine—Nausea—Doxorubicin—prostate cancer	0.000188	0.000194	CcSEcCtD
Doxylamine—Promazine—CYP3A4—prostate cancer	0.000172	0.00595	CrCbGaD
Doxylamine—Imipramine—CYP3A4—prostate cancer	0.00015	0.00521	CrCbGaD
Doxylamine—Amitriptyline—CYP3A4—prostate cancer	0.000149	0.00517	CrCbGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	4.77e-06	0.00103	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	4.75e-06	0.00103	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	4.71e-06	0.00102	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	4.69e-06	0.00101	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CALCA—prostate cancer	4.61e-06	0.000994	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CALCA—prostate cancer	4.59e-06	0.000991	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GHR—prostate cancer	4.58e-06	0.000988	CbGpPWpGaD
Doxylamine—HRH1—G alpha (q) signalling events—PIK3CA—prostate cancer	4.57e-06	0.000987	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GHR—prostate cancer	4.56e-06	0.000985	CbGpPWpGaD
Doxylamine—CHRM1—G alpha (q) signalling events—PIK3CA—prostate cancer	4.55e-06	0.000983	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PRKCQ—prostate cancer	4.52e-06	0.000976	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCQ—prostate cancer	4.51e-06	0.000973	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCL12—prostate cancer	4.5e-06	0.000971	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCL12—prostate cancer	4.48e-06	0.000968	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	4.45e-06	0.00096	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	4.43e-06	0.000957	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NRP1—prostate cancer	4.39e-06	0.000947	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NRP1—prostate cancer	4.37e-06	0.000944	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—ADRB2—prostate cancer	4.25e-06	0.000918	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—ADRB2—prostate cancer	4.24e-06	0.000915	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—TP53—prostate cancer	4.16e-06	0.000898	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—VAV3—prostate cancer	4.14e-06	0.000895	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—VAV3—prostate cancer	4.13e-06	0.000892	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCQ—prostate cancer	4.11e-06	0.000886	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCQ—prostate cancer	4.09e-06	0.000884	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	4.09e-06	0.000882	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VIP—prostate cancer	4.08e-06	0.00088	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNRH1—prostate cancer	4.08e-06	0.00088	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	4.07e-06	0.00088	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VIP—prostate cancer	4.06e-06	0.000878	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNRH1—prostate cancer	4.06e-06	0.000878	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—ITPR1—prostate cancer	4.02e-06	0.000868	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—ITPR1—prostate cancer	4.01e-06	0.000865	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GRP—prostate cancer	3.95e-06	0.000853	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LPAR1—prostate cancer	3.95e-06	0.000853	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GRP—prostate cancer	3.94e-06	0.00085	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LPAR1—prostate cancer	3.94e-06	0.00085	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PLCB2—prostate cancer	3.91e-06	0.000844	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LRP2—prostate cancer	3.91e-06	0.000844	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LRP2—prostate cancer	3.9e-06	0.000841	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PLCB2—prostate cancer	3.9e-06	0.000841	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—ADRB2—prostate cancer	3.86e-06	0.000833	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—ADRB2—prostate cancer	3.85e-06	0.000831	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CX3CL1—prostate cancer	3.83e-06	0.000828	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—P4HB—prostate cancer	3.83e-06	0.000828	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—P4HB—prostate cancer	3.82e-06	0.000825	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CX3CL1—prostate cancer	3.82e-06	0.000825	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—IL6—prostate cancer	3.81e-06	0.000822	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—VAV3—prostate cancer	3.76e-06	0.000813	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HIST1H2BG—prostate cancer	3.76e-06	0.000813	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—VAV3—prostate cancer	3.75e-06	0.00081	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HIST1H2BG—prostate cancer	3.75e-06	0.00081	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GRB7—prostate cancer	3.73e-06	0.000805	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDE4D—prostate cancer	3.73e-06	0.000805	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GRB7—prostate cancer	3.72e-06	0.000803	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDE4D—prostate cancer	3.72e-06	0.000803	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—ITPR1—prostate cancer	3.65e-06	0.000788	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—ITPR1—prostate cancer	3.64e-06	0.000786	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HIST1H4H—prostate cancer	3.63e-06	0.000785	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CXCL8—prostate cancer	3.63e-06	0.000784	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HIST1H4H—prostate cancer	3.62e-06	0.000782	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CXCL8—prostate cancer	3.62e-06	0.000782	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	3.62e-06	0.000781	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	3.61e-06	0.000779	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNG5—prostate cancer	3.55e-06	0.000766	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNG5—prostate cancer	3.54e-06	0.000764	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTHLH—prostate cancer	3.09e-06	0.000667	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFBR1—prostate cancer	3.09e-06	0.000667	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTHLH—prostate cancer	3.08e-06	0.000665	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFBR1—prostate cancer	3.08e-06	0.000665	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKR1C3—prostate cancer	3.04e-06	0.000656	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKR1C3—prostate cancer	3.03e-06	0.000654	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKACB—prostate cancer	3.02e-06	0.000653	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKACB—prostate cancer	3.01e-06	0.000651	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—THBS1—prostate cancer	2.95e-06	0.000637	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PPP3CA—prostate cancer	2.95e-06	0.000637	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—THBS1—prostate cancer	2.94e-06	0.000635	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PPP3CA—prostate cancer	2.94e-06	0.000635	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ANXA1—prostate cancer	2.91e-06	0.000627	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ANXA1—prostate cancer	2.9e-06	0.000625	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCZ—prostate cancer	2.85e-06	0.000616	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCZ—prostate cancer	2.84e-06	0.000614	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—prostate cancer	2.79e-06	0.000602	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—prostate cancer	2.78e-06	0.0006	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGFR4—prostate cancer	2.75e-06	0.000595	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PARP1—prostate cancer	2.75e-06	0.000595	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PARP1—prostate cancer	2.75e-06	0.000593	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGFR4—prostate cancer	2.75e-06	0.000593	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CALCA—prostate cancer	2.72e-06	0.000587	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CALCA—prostate cancer	2.71e-06	0.000586	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCL12—prostate cancer	2.66e-06	0.000574	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCL12—prostate cancer	2.65e-06	0.000572	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—prostate cancer	2.53e-06	0.000547	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—prostate cancer	2.52e-06	0.000545	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASP9—prostate cancer	2.5e-06	0.00054	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASP9—prostate cancer	2.49e-06	0.000539	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CD—prostate cancer	2.45e-06	0.000529	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CD—prostate cancer	2.44e-06	0.000527	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCQ—prostate cancer	2.43e-06	0.000524	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NGFR—prostate cancer	2.43e-06	0.000524	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCQ—prostate cancer	2.42e-06	0.000522	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NGFR—prostate cancer	2.42e-06	0.000522	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAP3K7—prostate cancer	2.4e-06	0.000517	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAP3K7—prostate cancer	2.39e-06	0.000516	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF10—prostate cancer	2.3e-06	0.000498	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF10—prostate cancer	2.3e-06	0.000496	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ADRB2—prostate cancer	2.28e-06	0.000492	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ADRB2—prostate cancer	2.27e-06	0.000491	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—JAK2—prostate cancer	2.25e-06	0.000486	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—JAK2—prostate cancer	2.24e-06	0.000484	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—MAP2K1—prostate cancer	2.24e-06	0.000484	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—MAP2K1—prostate cancer	2.23e-06	0.000482	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CD—prostate cancer	2.23e-06	0.000481	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VAV3—prostate cancer	2.22e-06	0.00048	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CD—prostate cancer	2.22e-06	0.000479	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VAV3—prostate cancer	2.22e-06	0.000479	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFBR2—prostate cancer	2.19e-06	0.000473	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFBR2—prostate cancer	2.18e-06	0.000472	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ITPR1—prostate cancer	2.16e-06	0.000466	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ITPR1—prostate cancer	2.15e-06	0.000464	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CB—prostate cancer	2.14e-06	0.000461	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CB—prostate cancer	2.13e-06	0.00046	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF1R—prostate cancer	2.06e-06	0.000445	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF1R—prostate cancer	2.06e-06	0.000444	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CXCL8—prostate cancer	2.05e-06	0.000443	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CXCL8—prostate cancer	2.05e-06	0.000442	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—JAK2—prostate cancer	2.04e-06	0.000441	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—JAK2—prostate cancer	2.04e-06	0.00044	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LPL—prostate cancer	1.98e-06	0.000427	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LPL—prostate cancer	1.97e-06	0.000425	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—IL2—prostate cancer	1.96e-06	0.000424	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PDGFRB—prostate cancer	1.96e-06	0.000423	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—IL2—prostate cancer	1.96e-06	0.000422	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PDGFRB—prostate cancer	1.95e-06	0.000422	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CB—prostate cancer	1.94e-06	0.000419	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CB—prostate cancer	1.93e-06	0.000417	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ITGB3—prostate cancer	1.91e-06	0.000412	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ITGB3—prostate cancer	1.9e-06	0.000411	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	1.86e-06	0.000402	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	1.86e-06	0.000401	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ERBB3—prostate cancer	1.85e-06	0.0004	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGFR2—prostate cancer	1.85e-06	0.000399	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ERBB3—prostate cancer	1.85e-06	0.000399	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGFR2—prostate cancer	1.84e-06	0.000398	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL2—prostate cancer	1.78e-06	0.000385	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL2—prostate cancer	1.78e-06	0.000383	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TERT—prostate cancer	1.77e-06	0.000383	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TERT—prostate cancer	1.77e-06	0.000382	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HIF1A—prostate cancer	1.7e-06	0.000367	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HIF1A—prostate cancer	1.69e-06	0.000365	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LEP—prostate cancer	1.66e-06	0.000358	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LEP—prostate cancer	1.65e-06	0.000357	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CAV1—prostate cancer	1.64e-06	0.000354	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CAV1—prostate cancer	1.64e-06	0.000353	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KDR—prostate cancer	1.62e-06	0.000351	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KDR—prostate cancer	1.62e-06	0.000349	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ESR1—prostate cancer	1.58e-06	0.000342	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ESR1—prostate cancer	1.58e-06	0.00034	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BAD—prostate cancer	1.54e-06	0.000333	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BAD—prostate cancer	1.54e-06	0.000332	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APC—prostate cancer	1.5e-06	0.000323	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	1.5e-06	0.000323	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	1.49e-06	0.000322	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APC—prostate cancer	1.49e-06	0.000322	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGF—prostate cancer	1.48e-06	0.000319	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IRS1—prostate cancer	1.48e-06	0.000319	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IRS1—prostate cancer	1.47e-06	0.000318	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGF—prostate cancer	1.47e-06	0.000318	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GSK3B—prostate cancer	1.44e-06	0.00031	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	1.43e-06	0.000309	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—INS—prostate cancer	1.42e-06	0.000306	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—INS—prostate cancer	1.41e-06	0.000305	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CREBBP—prostate cancer	1.39e-06	0.000299	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	1.38e-06	0.000298	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF1—prostate cancer	1.37e-06	0.000296	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF1—prostate cancer	1.36e-06	0.000295	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EGFR—prostate cancer	1.36e-06	0.000294	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	1.36e-06	0.000293	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	1.32e-06	0.000286	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	1.32e-06	0.000285	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	1.31e-06	0.000284	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	1.31e-06	0.000283	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	1.3e-06	0.000281	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	1.3e-06	0.000281	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	1.3e-06	0.00028	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	1.3e-06	0.00028	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—KRAS—prostate cancer	1.29e-06	0.000278	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	1.28e-06	0.000277	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FGF2—prostate cancer	1.26e-06	0.000272	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FGF2—prostate cancer	1.25e-06	0.000271	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOS3—prostate cancer	1.24e-06	0.000268	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOS3—prostate cancer	1.24e-06	0.000267	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JAK2—prostate cancer	1.21e-06	0.000261	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JAK2—prostate cancer	1.2e-06	0.00026	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	1.18e-06	0.000255	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	1.18e-06	0.000255	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MDM2—prostate cancer	1.18e-06	0.000254	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MDM2—prostate cancer	1.17e-06	0.000253	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ERBB2—prostate cancer	1.16e-06	0.000251	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	1.16e-06	0.00025	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	1.15e-06	0.000247	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	1.14e-06	0.000247	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCL8—prostate cancer	1.1e-06	0.000238	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	1.1e-06	0.000237	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	1.08e-06	0.000232	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	1.07e-06	0.000231	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	1.06e-06	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	1.06e-06	0.000229	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASP3—prostate cancer	1.05e-06	0.000228	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL2—prostate cancer	1.05e-06	0.000227	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASP3—prostate cancer	1.05e-06	0.000227	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL2—prostate cancer	1.05e-06	0.000227	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6—prostate cancer	1.05e-06	0.000226	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6—prostate cancer	1.04e-06	0.000225	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCND1—prostate cancer	1.03e-06	0.000222	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCND1—prostate cancer	1.02e-06	0.000221	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	1.02e-06	0.000219	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	1.01e-06	0.000219	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP9—prostate cancer	9.96e-07	0.000215	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP9—prostate cancer	9.93e-07	0.000214	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	9.92e-07	0.000214	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTEN—prostate cancer	9.9e-07	0.000214	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	9.89e-07	0.000214	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTEN—prostate cancer	9.87e-07	0.000213	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—prostate cancer	9.66e-07	0.000209	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	9.63e-07	0.000208	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EP300—prostate cancer	9.44e-07	0.000204	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EP300—prostate cancer	9.41e-07	0.000203	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SRC—prostate cancer	9.18e-07	0.000198	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SRC—prostate cancer	9.15e-07	0.000198	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFA—prostate cancer	8.94e-07	0.000193	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	8.92e-07	0.000192	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—prostate cancer	8.86e-07	0.000191	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—prostate cancer	8.83e-07	0.000191	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MYC—prostate cancer	8.23e-07	0.000178	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFB1—prostate cancer	8.21e-07	0.000177	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MYC—prostate cancer	8.2e-07	0.000177	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	8.18e-07	0.000177	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGFR—prostate cancer	8.05e-07	0.000174	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGFR—prostate cancer	8.02e-07	0.000173	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KRAS—prostate cancer	7.6e-07	0.000164	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KRAS—prostate cancer	7.58e-07	0.000164	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	6.99e-07	0.000151	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	6.96e-07	0.00015	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TP53—prostate cancer	6.76e-07	0.000146	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TP53—prostate cancer	6.74e-07	0.000145	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6—prostate cancer	6.19e-07	0.000134	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6—prostate cancer	6.17e-07	0.000133	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—prostate cancer	5.71e-07	0.000123	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—prostate cancer	5.69e-07	0.000123	CbGpPWpGaD
